Background: Dynamic arterial elastance (Ea dyn ) has been proposed as an indicator of vascular tone that predicts the decrease in arterial pressure in response to changes in norepinephrine (NE). The purpose of this study was to determine whether Ea dyn measured by uncalibrated pulse contour analysis (UPCA) can predict a decrease in arterial pressure when the NE dosage is decreased. Methods: We conducted a prospective study in a university hospital intensive care unit. Patients with vasoplegic syndrome for whom the intensive care physician planned to decrease the NE dosage were included. Haemodynamic and UPCA (VolumeView and FloTrac; Edwards Lifesciences, Irvine, CA, USA) values were obtained before and after decreasing the NE dosage. Responders were defined by a >10% decrease in mean arterial pressure (MAP). Results: Of 35 patients included, 11 (31%) were pressure responders with a median decrease of 13%. Ea dyn was correlated to systolic arterial pressure (SAP) (r¼0.255; P¼0.033), diastolic arterial pressure (r¼0.271; P¼0.024), MAP (r¼0.310; P¼0.009), heart rate (r¼0.543; P¼0.0001), and transthoracic echography cardiac output (r¼0.264; P¼0.024). Baseline Ea dyn was correlated with MAP changes (r¼0.394; P¼0.019) and SAP changes (r¼0.431; P¼0.009). Ea dyn predicted the decrease in arterial pressure with an area under the receiver-operating-characteristic curve of 0.84 (95% confidence interval: 0.70e0.97). The best cut-off was 0.90. Conclusions: The present study confirms the ability of Ea dyn measured by UPCA to predict an arterial pressure response to a decrease in NE. Ea dyn may constitute an easy-to-use functional approach to arterial tone assessment regardless of the monitor used to measure its determinant. Clinical trial registration: DRCIT95.
Editor's key points
Dynamic arterial elastance is a potential measure of arterial tone that may respond to changes in vasopressor drug dosage. Previous studies of dynamic arterial elastance have used cardiac-output-calibrated pulse contour analysis, but this has been shown to be an inaccurate measure of cardiac output. In this study, critically ill patients with vasoplegia were studied using uncalibrated pulse contour analysis. There was a correlation between dynamic arterial elastance and arterial pressure changes in response to a reduction in norepinephrine dose. However, the study was small, and the patients were heterogeneous, so the results should be interpreted with caution.
Norepinephrine (NE) is the first-line treatment for vasoplegic syndrome recommended by international guidelines.
1,2 Dynamic arterial elastance (Ea dyn ) has been proposed as an indicator of arterial tone that can predict NE-dependent arterial pressure. 3 Ea dyn is calculated using the ratio of respiratory pulse-pressure variation (PPV) over the respiratory stroke volume variation (SVV). Guinot and colleagues 4 demonstrated a decrease in the duration of NE treatment with the use of Ea dyn . 4 To date, studies that have validated Ea dyn at bedside have used cardiac-output (CO) calibrated pulse contour analysis 3 (PiCCO™ and PULSION™) or oesophageal Doppler. 5 Such monitoring systems need dedicated and specific arterial line and venous access that may limit their use at bedside. In addition to CO calibrated pulse contour analysis, CO uncalibrated pulse contour analysis (UPCA) has been developed and is considered less invasive. Nevertheless, one limitation of the latter CO monitoring is inaccuracy of CO measurement in patients who are being treated with NE. 6, 7 Mahjoub and colleagues 8 have demonstrated that CO measured by UPCA is inaccurate and unable to track CO trends with NE. These limitations may affect the predictability of Ea dyn . To date, no study has evaluated the ability of Ea dyn measured by UPCA to assess the arterial-pressure response to a decreased dose of NE. We tested the hypothesis that Ea dyn calculated from UPCA predicts the arterial-pressure response to an NE decrease in patients treated with NE.
Methods

Ethics
The study objectives and procedures were approved by the local ethics committee (Le Comit e de Protection des Personnes Nord Ouest II CHU, Place Victor Pauchet, 80054 Amiens Cedex 1, France, RNI 2016-28). All subjects received written information about the study and provided their consent to participate. The present paper was drafted in compliance with the Strengthening the Reporting of Observational Studies in Epidemiology checklist for cohort studies. 9 
Patients
A prospective, observational study was conducted at the Amiens University Hospital intensive care unit (ICU) from July 2016 to March 2017. The inclusion criteria were all consecutive patients with a diagnosis of vasoplegic syndrome, treated with NE, for whom the attending physician decided to decrease the NE dosage. The vasoplegic syndrome was defined as persistent arterial hypotension with normal or high CO and low systemic vascular resistance (SVR). 10 The exclusion criteria were patients treated with epinephrine or dobutamine, arrhythmia, intra-abdominal hypertension, and patients younger than 18 yr. All patients were sedated with a continuous infusion of midazolam and sufentanil and were ventilated in volumecontrolled mode. In our institution, the dosage of NE is decreased by 3.3 mg min À1 every 15 min as long as the mean arterial pressure (MAP) remains higher than 65 mm Hg. The indication for decreasing the dosage of NE was left to the physician's discretion. Only a one-step NE dose reduction was assessed in this study. 3 
Haemodynamic variables
We measured the UPCA CO (CO UPCA ) and SVV using UPCA (Monitor Vigileo, FloTrac ™ pressure transducer software version 4.0; Edwards Lifesciences, Irvine, CA, USA), and obtained the average of five successive values. We also measured the transthoracic echography CO (CO TTE ) by transthoracic echocardiography (CX50 Ultrasound System and S5-1 Sector Array Transducer; Philips Medical System, Suresnes, France). The diameter of the left ventricular outflow tract was measured on a long-axis parasternal view at the time of patient inclusion. The aortic velocityetime integral (VTIAo) was measured with pulsed Doppler on a five-chamber apical view. Stroke volume (SV; ml) was calculated as VTIAo Â aortic area. CO TTE (litres min
À1
) was calculated as SV Â heart rate (HR).
PPV was automatically calculated by the Philips monitoring system and represents the average of five successive values.
11
All SVV and PPV values were sampled at the same time on radial arterial line. Dynamic arterial elastance (Ea dyn ) was defined as the ratio of PPV/SVV.
We calculated SVR as SVR¼MAP e CVP/CO TTE * 80 (dynes s cm À5 ). We calculated the static arterial compliance (C A ) by using transthoracic SV (SV TTE ) and SV Vigileo (SV UCP ) as C A TTE ¼SV TTE /arterial pulse pressure (PP) (ml mmHg
À1
) and C A UCP ¼SV UCP /PP (ml mmHg À1 ). We calculated the net arterial elastance (E A ) by using transthoracic SV (SV TTE ) and SV vigileo (SV UCP ) as E A TTE ¼MAP/SV TTE (ml mmHg À1 ) and E A UCP ¼MAP/ SV UCP (ml mmHg À1 ).
Study protocols
The following clinical data were recorded: age, sex, surgical/ medical history, indications for NE treatment, and Simplified Acute Physiology Score 2. The following haemodynamic measurements were recorded at baseline, with the patient connected to the ventilator: HR, systolic arterial pressure (SAP), MAP, diastolic arterial pressure (DAP), central venous pressure (CVP), SVV, PPV, CO UPCA , CO TTE , central venous saturation (ScVO 2 ), and arterial lactate. The dose of NE was decreased. After the stabilisation of haemodynamic variables, as assessed by the absence of variation of MAP by >10% over a 30 min period, a second set of measurements (HR, SAP, MAP, DAP, CVP, CVP, SVV, PPV, CO UPCA , CO TTE , ScVO 2 , and arterial lactate) was recorded. The ventilator settings and sedations were kept constant throughout the study period.
Statistical analysis
A sample of 30 patients was calculated to be sufficient to demonstrate that Ea dyn could predict a decrease in arterial pressure in response to decreasing the NE dose with an area under the receiver-operating-characteristic (ROC) curve (AUC) greater than 0.80, a power of 80%, and an a risk of 0.05. Thirtyfive patients were, therefore, retained according to the exclusion criteria. The coefficient of variation (CV), precision, and least significant change (LSC) for MAP were calculated on the overall population. The LSC is the least amount of MAP change that can be considered to be statistically significant (i.e. the minimum percent change between two successive measurements that can be considered not to be caused by random error and, therefore, representing a real change in MAP Linear correlations were tested with the Spearman rank method. Because we have evaluated the predictability of Ea dyn in a heterogeneous population, we analysed the associations between cardiovascular variables (HR, SAP, MAP, DAP, SV, E adyn , CO, E A TTE , and SVR) and MAP changes by using a univariate logistic model. Variables with a P-value of 0.10 were then included in a multivariate logistic model with a backward-selection procedure. An ROC curve was established for Ea dyn and baseline MAP to predict a decrease of greater than 10% of MAP with NE decrease. The AUC for each variable were compared using the test described by DeLong and colleagues. 12 Differences with a P-value <0.05 were considered statistically significant. IBM SPSS Statistics 24 ® (IBM ® ) software was used to carry out the statistical analysis.
Results
A total of 35 patients were subsequently included. None of the included patients were excluded (Fig 1) . The most frequent causes of vasoplegic syndrome were sepsis and postoperative cardiac surgery (Table 1) . Eleven (31%) of the 35 patients were classified as arterial-pressure responders because their MAP Effects of decreased NE dose on haemodynamic parameters according to pressure response
At baseline, the patients did not differ in terms of NE dosage (Table 2) . At baseline, HR and Ea dyn were lower in pressure responders compared with pressure non-responder patients ( Table 2 , Fig. 2 ). Other haemodynamic variables did not differ between the two groups of patients. In pressure responders, a decrease in NE significantly decreased the arterial pressure (SAP, DAP, and MAP), SVV, and SVR. In pressure nonresponders, a decrease in NE decreased DAP and MAP, and increase CO UPCA ( Table 2) .
Effects of decreased NE dose on arterial load variables according to pressure response
Arterial compliance and net arterial elastance were higher and lower in pressure-responder patients. In pressure responders, Predictability to discriminate decreased MAP in response to NE changes Ea dyn predicted a decrease in arterial pressure with an AUC of 0.84 (95% CI: 0.70e0.97). The best cut-off was 0.90 with a sensitivity of 91% (95% CI: 59e100), a specificity of 80% (95% CI: 58e93%), a positive likelihood ratio of 4.55, and a negative likelihood ratio of 0.11 (Fig 3) .
C A TTE , baseline MAP, and SVR were not predictive, with an AUC of 0.46 (95% CI: 0.26e0.68; P¼0.749), 0.39 (95% CI: 0.19e0.59; P¼0.285), and 0.41 (95% CI: 0.19e0.63; P¼0.413), respectively.
Discussion
The main result of the present study is that Ea dyn calculated from dynamic respiratory preload indices measured by UPCA (FloTrac) can predict the arterial-pressure response to a decrease in NE. The best cut-off (i.e. 0.90) to distinguish responders from non-responders is close to the previously demonstrated value. 3 One important question remains the physiological significance of Ea dyn . This parameter was initially described as a functional dynamic approach of vascular tone. 13 Ea dyn may be a measure of arterial stiffness that is one component of the vasomotor tone. A low Ea dyn whereas a patient is treated by NE may suggest that SV variations induced low variations in PP caused by the low central vasomotor tone. In this way, pressure-responder patients have higher baseline arterial compliance, whereas SVR values were not different. Most studies analysing Ea dyn have demonstrated inconsistent associations between Ea dyn and arterial pressure, and different components of arterial load (total peripheral resistance and arterial compliance). 3,4,14e16 These findings may depend on baseline vasomotor tone, which is not constant, and varies with age and administration of vasopressor or vasodilator, 19 and the use of vasoactive agents that change blood flow, mechanical properties of arteries (i.e. arterial stiffness), and vasomotor tone (peripheral resistance), and thus, the relation between flow and pressure. 20, 21 We calculated blood pressure from a radial artery signal, which may have differed from the aortic pressure signal. Such measurement may be inaccurate, because NE can alter the peripheral vasomotor tone and PP wave amplification. For this reason, we assessed the changes of blood pressure and effective arterial elastance by using MAP. Femoral and radial MAP measurements show a good level of agreement (regardless of the use of vasoactive drugs), and the two measurements are interchangeable. 22 We also observed similar trend of changes of arterial load parameters in the present study and our previous study, which have used femoral arterial-pressure measurement. 3 In both studies, NE decrease was associated with an increase of arterial compliance and a decrease of effective arterial elastance. Our study has some limitations. We may have included bias because we have studied heterogeneous patients with several aetiologies of vasoplegic syndrome. Even so, Ea dyn remained the only factor associated with MAP changes, strengthening the results of the study. Further interventional studies using algorithms are required to confirm the performance of this index measured by FloTrac. In addition, we studied a one-step NE dose reduction that was similar in the entire population. Therefore, we cannot generalise these results to other larger steps in NE dose decrease. One question could be the validity of the mathematical coupling equation, as respiratory variations in SV and PP were measured using the same signal. García and colleagues 5 have demonstrated that, when calculated from two independent signals, Ea dyn is still predictive of the arterialpressure response to fluid challenge. We excluded patients treated with dobutamine, which can represent 30% of the patients admitted to the ICU. Dobutamine has vasodilator effects that could alter the predictability or the thresholds of Ea dyn . In these situations, specific additional studies are needed to validate the predictability and reproducibility of Ea dyn .
The present study confirms the ability of Ea dyn measured by UPCA to predict an arterial-pressure response to a decrease in NE. Ea dyn may constitute an easy-to-use functional approach to arterial tone assessment regardless of the monitor used to measure its determinant.
